Additionally, in HIF2α low/− clear cell renal cell carcinoma (ccRCC), FTO displays elevated expression levels, leading to increased sensitivity of ccRCC to BRD9 inhibitors (23). This evidence concerns the gene BRD9 and nonpapillary renal cell carcinoma.